Treatment of movement disorders with drug therapy

• US 7,925,353 B1
• Filed: 03/13/2006
• Issued: 04/12/2011
• Est. Priority Date: 03/28/2003
• Status: Active Grant

• Current Assignee: Medtronic Minimed Incorporated (Medtronic Plc)
• Original Assignee: Alfred E. Mann Foundation For Scientific Research
• Inventors: Whitehurst, Todd K., McGivern, James P.
• Primary Examiner(s): Layno; Carl H
• Assistant Examiner(s): Porter, Jr.; Gary A
• Application Number:
  US11/374,799
• Time in Patent Office: 1,856 Days
• Field of Search: 607/3, 607/45, 607/46, 607/48, 607116-118, 607/49
• US Class Current: 607/45
• CPC Class Codes: A61N 1/36003 of motor muscles, e.g. for walking assistance
• CPC Class Codes: A61N 1/3787 from an external energy source

Abstract

Introducing one or more stimulating drugs to the vagus nerve and/or one or more branches of the vagus nerve to treat movement disorders uses at least one implantable system control unit (SCU) with an implantable pump with at least one infusion outlet. Optional electrical stimulation may additionally be supplied by an implantable signal/pulse generator (IPG) with one or more electrodes. In certain embodiments, a single SCU provides one or more stimulating drugs and the optional electrical stimulation. In some embodiments, one or more sensed conditions are used to adjust stimulation parameters.

Claims

1. A method of operating an implantable stimulator to control a movement disorder, the method comprising:

implanting a stimulator having at least one infusion outlet into a patient; and

delivering at least one stimulus to at least one vagus nerve of the patient in accordance with one or more stimulation parameters configured to treat a movement disorder, wherein the at least one stimulus comprises at least one drug delivered through the at least one infusion outlet of the stimulator;

wherein the at least one drug increases activity of the at least one vagus nerve in order to, at least in part, alleviate the movement disorder.

2. The method of claim 1, wherein the stimulator further includes at least two electrodes, and wherein the stimulus further comprises electrical stimulation delivered to the at least one vagus nerve via the at least two electrodes.

3. The method of claim 2, wherein the electrical stimulation is delivered at a frequency less than about 100 Hz.

4. The method of claim 1, wherein the at least one drug comprises a neural depolarizing agent.

5. The method of claim 4, wherein the neural depolarizing agent is succinylcholine.

6. The method of claim 1, wherein the at least one drug comprises at least one of an excitatory neurotransmitter, an excitatory neurotransmitter agonist, an inhibitory neurotransmitter antagonist, an agent that increases the level of an excitatory neurotransmitter, and an agent that decreases the level of an inhibitory neurotransmitter.

7. The method of claim 1, wherein the drug is at least one of acetylcholine and bethanechol.

8. The method of claim 1, further comprising sensing at least one condition and using the at least one sensed condition to automatically adjust one or more of the stimulation parameters governing the delivery of the at least one drug.

9. The method of claim 8, wherein the at least one sensed condition is one or more of acceleration, electromyographic activity, electrical activity of a neural population, a neurotransmitter level, change in a neurotransmitter level, a neurotransmitter breakdown product level, change in a neurotransmitter breakdown product level, a medication level, change in a medication level, a drug level, change in a drug level, a hormone level, change in a hormone level, an enzyme level, change in an enzyme level, an interleukin level, change in an interleukin level, a cytokine level, change in a cytokine level, a lymphokine level, change in a lymphokine level, a chemokine level, change in a chemokine level, a growth factor level, change in a growth factor level, level of a bloodborne substance, change in level of a bloodborne substance, level of a substance in the interstitial fluid, change in level of a substance in the interstitial fluid, a substance in the cerebrospinal fluid, and change in the level of a substance in the cerebrospinal fluid.

10. The method of claim 1, wherein said stimulator comprises a catheter, said catheter being connected to and extending from said stimulator and comprising said infusion outlet.

11. The method of claim 10, further comprising

implanting the stimulator at a location remote from the at least one vagus nerve;

and

tunneling the catheter subcutaneously from the stimulator to the at least one vagus nerve.

12. The method of claim 1, wherein said movement disorder comprises at least one of Parkinson'"'"'s disease and essential tremor.

13. The method of claim 10, further comprising delivering the at least one drug to the at least one vagus nerve via the catheter.

14. A method of treating a patient with a movement disorder, comprising:

providing a stimulator;

configuring one or more stimulation parameters to treat a movement disorder;

programming said stimulator with said one or more stimulation parameters; and

applying said stimulus with said stimulator to at least one vagus nerve within said patient in accordance with said one or more stimulation parameters;

wherein said stimulus comprises at least one drug that increases activity of the at least one vagus nerve in order to at least in part alleviate said movement disorder.

15. The method of claim 14, wherein said stimulus further comprises electrical stimulation applied to said at least one vagus nerve.

16. The method of claim 14, wherein said at least one drug comprises a neural depolarizing agent.

17. The method of claim 16, wherein the neural depolarizing agent comprises succinylcholine.

18. The method of claim 14, wherein the at least one drug comprises at least one of an excitatory neurotransmitter, an excitatory neurotransmitter agonist, an inhibitory neurotransmitter antagonist, an agent that increases the level of an excitatory neurotransmitter, and an agent that decreases the level of an inhibitory neurotransmitter.

19. The method of claim 14, wherein the drug comprises at least one of acetylcholine and bethanechol.

20. The method of claim 14, further comprising sensing at least one condition and using the at least one sensed condition to automatically adjust one or more of the stimulation parameters.